Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study
Clinical Pharmacology in Drug Development · 2024-04 · 13 (4) · 326-340
DOI: 10.1002/cpdd.1388 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 05.03.2024. Verfasst von Borje Darpo und 3 weiteren Autor:innen. Beteiligte Einrichtung: ERT, Rochester, NY, USA. Hauptthemen laut MEDLINE: Fluoroquinolones, Electrocardiography, Acetates, Indoles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Etrasimod is an investigational, once‐daily, oral, selective sphingosine 1‐phosphate receptor 1,4,5 modulator used as an oral treatment option for immune‐mediated inflammatory disorders. This randomized, double‐blind, placebo‐ and positive‐controlled, parallel‐group, healthy adult study investigated etrasimod's effect on the QT interval and other electrocardiogram parameters. All participants received etrasimod‐matched placebo on day 1. Group A received once‐daily, multiple ascending doses of etrasimod (2‐4 mg) on days 1‐14 and moxifloxacin‐matched placebo on days 1 and 15. Group B received etrasimod‐matched placebo on days 1‐14 and either moxifloxacin 400 mg or moxifloxacin‐matched placebo on days 1 and 15. The primary analysis was a concentration‐QTc analysis using a corrected QT interval by Fridericia (QTcF). The etrasimod concentration‐QTc analysis predicted placebo‐corrected change from baseline QTcF (ΔΔQTcF) values and associated 90% confidence intervals remained
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ERT, Rochester, NY, USA.
- Arena Pharmaceuticals, San Diego, CA, USA, a wholly-owned subsidiary of Pfizer Inc, New York, NY, USA.
Zitieren
APA
Darpo, B., Connor, K., Cabell, C. H., & Grundy, J. S. (2024). Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study. Clinical Pharmacology in Drug Development, 13(4), 326-340. https://doi.org/10.1002/cpdd.1388
Vancouver
Darpo B, Connor K, Cabell CH, Grundy JS. Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study. Clinical Pharmacology in Drug Development. 2024;13(4):326-340. doi:10.1002/cpdd.1388
BibTeX
@article{Darpo2024,
author = {Darpo, Borje and Connor, Kalvin and Cabell, Christopher H and Grundy, John S},
title = {Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
volume = {13},
number = {4},
pages = {326--340},
doi = {10.1002/cpdd.1388}
}
EUVIMED